Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Procedure (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Product (Reagents and Consumables, Instruments, Software), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Others), By Application (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other), By End User (Fertility Centers, Hospitals, Diagnostic Centers, Research Centers and Academic Labs), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 660.67 Million
CAGR (2026-2031)	8.36%
Fastest Growing Segment	Polymerase Chain Reaction (PCR)
Largest Market	Europe
Market Size (2031)	USD 1069.54 Million

Market Overview

The Global Preimplantation Genetic Testing Market is projected to grow from USD 660.67 Million in 2025 to USD 1069.54 Million by 2031 at a 8.36% CAGR. Preimplantation Genetic Testing (PGT) constitutes the genetic evaluation of embryos created through in vitro fertilization prior to uterine transfer, aiming to identify chromosomal abnormalities or specific monogenic disorders. The market’s expansion is primarily driven by global demographic shifts, including a rising average maternal age associated with increased risk of genetic anomalies, and continuous advancements in assisted reproductive technologies enhancing PGT efficacy. According to the European Society of Human Reproduction and Embryology PGT Consortium, approximately 9,971 biopsy cycles for PGT were reported in participating centers in 2023.

Moreover, heightened patient and clinician awareness regarding the benefits of reducing inherited genetic disease transmission also propels market growth. However, a significant impediment to market expansion remains the substantial cost associated with PGT procedures and the limited or inconsistent insurance reimbursement policies across various healthcare systems, potentially hindering broader adoption.

Key Market Drivers

Technological advancements in genetic testing represent a pivotal driver for the global Preimplantation Genetic Testing market, enabling more precise and comprehensive embryo evaluations. The continuous evolution of sequencing techniques, particularly Next-Generation Sequencing, allows for enhanced accuracy in detecting chromosomal abnormalities and specific monogenic disorders. For instance, according to Thermo Fisher Scientific, in July 2023, the company launched two new NGS-based research tools, the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit, designed to support preimplantation genetic testing for aneuploidy. These innovations improve the efficiency and reliability of PGT procedures, expanding their applicability and fostering greater confidence among clinicians and prospective parents.

The rising incidence of infertility globally also significantly propels the Preimplantation Genetic Testing market, increasing the demand for assisted reproductive technologies where PGT is often integrated. As more individuals and couples seek fertility treatments, the necessity for genetic screening of embryos intensifies to improve pregnancy outcomes and reduce the risk of genetic conditions. According to the World Health Organization, in April 2023, approximately 17.5% of the adult population worldwide experiences infertility. This widespread challenge drives the adoption of IVF procedures, creating a larger patient pool for PGT. Consequently, the market sees growth as PGT becomes a more routine component of fertility care, aiming to maximize the success rates of embryo transfer. According to preliminary data from the European IVF Monitoring Consortium of the European Society of Human Reproduction and Embryology, presented in March 2024, a total of 1,103,633 Assisted Reproductive Technology treatment cycles were reported across 37 European countries in 2021.

Download Free Sample Report

Key Market Challenges

A significant challenging factor impeding the expansion of the Global Preimplantation Genetic Testing Market is the substantial cost associated with PGT procedures and the limited or inconsistent insurance reimbursement policies across various healthcare systems. This financial barrier directly restrains market growth by making PGT inaccessible for a considerable segment of potential patients. High out-of-pocket expenses, coupled with the often already costly in vitro fertilization cycles, deter individuals from pursuing PGT despite its clinical benefits in identifying genetic anomalies.

The lack of standardized and comprehensive reimbursement policies across different countries and regions contributes to financial uncertainty for prospective parents, further hindering broader adoption. Where PGT costs are not adequately covered, patients bear the full financial burden, which can be prohibitive. According to CARE Fertility and Women's Health, in 2025, Preimplantation Genetic Testing for Aneuploidy (PGT-A) in the United States alone cost between $2,500 and $4,000 per cycle, with more complex testing for single gene disorders (PGT-M) ranging from $7,000 to $12,000 per cycle. Such elevated costs, often excluded from extensive insurance coverage, force many individuals to forgo these advanced genetic evaluations, thereby limiting the overall growth trajectory and market penetration of preimplantation genetic testing services globally.

Key Market Trends

Artificial Intelligence integration in embryo assessment is significantly reshaping the Global Preimplantation Genetic Testing Market by introducing enhanced objectivity and precision to embryo selection. This trend moves beyond traditional morphological evaluation, employing advanced algorithms to analyze complex data from time-lapse imaging and other embryological parameters, thereby reducing human subjectivity and improving the consistency of grading. Studies report that AI models can achieve 10 to 25% higher accuracy in predicting embryo viability and implantation potential compared to traditional morphological assessment by embryologists, according to a review published in Reproductive Biology and Endocrinology, December 2025, in the article 'Artificial Intelligence in Routine IVF Practice'. This increased accuracy allows for more confident single-embryo transfers and optimizes overall in vitro fertilization outcomes, bolstering clinician and patient confidence in PGT procedures.

The expanding adoption of non-invasive preimplantation genetic testing (niPGT) represents another pivotal trend, driven by the desire to minimize potential risks to embryos associated with invasive biopsy procedures. niPGT analyzes cell-free DNA released into the embryo culture medium, circumventing the need for trophectoderm biopsy. This non-invasive approach is appealing due to its potential to reduce physical stress on the embryo and simplify laboratory workflows. For instance, research published in Reproductive Sciences, October 2025, in the article 'Optimizing Non-Invasive PGT-A: A Multi-Factorial Approach for Enhanced Accuracy and Seamless Integration Into Clinical IVF', indicated that an optimized niPGT-A workflow achieved a superior Positive Predictive Value of 92.1% and accuracy of 91.3%, outperforming conventional PGT-A. Such advancements are critical for broader acceptance, as they enhance diagnostic reliability while addressing ethical considerations and patient safety concerns, thereby facilitating greater market penetration.

Segmental Insights

The Polymerase Chain Reaction (PCR) segment is experiencing rapid growth in the Global Preimplantation Genetic Testing Market, primarily due to its inherent technical advantages and established reliability. PCR offers high accuracy and sensitivity in detecting genetic abnormalities from the minute DNA quantities available in embryonic cells. This technology's ability to amplify specific genome segments extensively enhances the identification of chromosomal irregularities and monogenic diseases, crucial for effective preimplantation diagnosis. Furthermore, its cost-effectiveness and relatively quick turnaround time make it a highly favored method for fertility clinics and diagnostic centers, supporting its significant market penetration and continuous expansion within this specialized field.

Regional Insights

Europe leads the global preimplantation genetic testing market due to its advanced healthcare infrastructure, particularly a robust network of fertility clinics integrating assisted reproductive technologies. The region benefits from a diverse, yet often favorable, regulatory landscape, where several countries permit broad applications of preimplantation genetic testing for aneuploidy screening and monogenic disease prevention. High patient awareness regarding genetic disorders, combined with increasing maternal age, further drives demand for these services, ensuring Europe's continued market leadership through strong clinical adoption and ethical governance.

Recent Developments

• In December 2025, CCRM Fertility continued to highlight its extensive contributions to the field of preimplantation genetic testing for aneuploidy (PGT-A). The company emphasized its long-standing role as a pioneer in fertility treatment and research, having made significant breakthroughs in PGT-A over more than three decades. CCRM Fertility’s ongoing research and development efforts focus on refining PGT-A as a crucial embryo selection tool in in vitro fertilization, aiming to improve implantation rates and increase the chances of chromosomally normal live births within the global Preimplantation Genetic Testing Market.
• In October 2025, RMA of New York, a leading fertility practice within US Fertility, earned significant scientific recognition at the American Society for Reproductive Medicine (ASRM) conference. Researchers presented findings from a study that investigated whether preimplantation genetic testing for aneuploidy (PGT-A) influenced the number of embryo transfers or the timeline to live birth in donor egg recipients. The study concluded that PGT-A did not show a statistically significant association, emphasizing the importance of individualized patient-provider discussions regarding PGT-A as an embryo selection tool within the global Preimplantation Genetic Testing Market.
• In October 2025, Genomic Prediction Inc., a prominent company specializing in advanced genetic testing, initiated a federal lawsuit against former employees and Nucleus Genomics, Inc. The lawsuit alleged the misappropriation of trade secrets and proprietary technology, including intellectual property related to embryonic DNA sequencing and amplification methods. Genomic Prediction contended that these actions were part of an orchestrated plan by Nucleus Genomics to launch competing preimplantation genetic testing (PGT) products and services, aiming to leverage the alleged stolen trade secrets. This legal development signifies competitive activity and potential new product entries in the global Preimplantation Genetic Testing Market.
• In April 2025, CooperSurgical, a prominent entity in fertility and women's health, joined The Wyatt Foundation's and The Conceive Fertility Foundation's 2025 IVF grant program. As part of this collaboration, CooperSurgical offered an additional $1,000 to each grant recipient, specifically earmarked for preimplantation genetic testing (PGT) services. This initiative aimed to alleviate financial barriers for patients seeking fertility care and underscores CooperSurgical's commitment to advancing access to essential genetic screening technologies within the global Preimplantation Genetic Testing Market. The support facilitated broader utilization of PGT to identify genetic abnormalities in embryos before pregnancy, enhancing patient outcomes.

Key Market Players

• Sutter Health
• Acacia Research Corporation
• CooperSurgical, Inc.
• F. Hoffmann-La Roche AG
• Genea Pty Limited
• Genesis Genetics
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Illumina, Inc.
• Natera, Inc.

By Procedure	By Product	By Technology	By Application	By End User	By Region
Preimplantation Genetic Screening Preimplantation Genetic Diagnosis	Reagents and Consumables Instruments Software	Next Generation Sequencing (NGS) Polymerase Chain Reaction (PCR) Fluorescent In-Situ Hybridization (FISH) Others	Chromosomal Abnormalities X-linked Diseases Embryo Testing Aneuploidy Screening HLA Typing Other	Fertility Centers Hospitals Diagnostic Centers Research Centers Academic Labs	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Preimplantation Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Preimplantation Genetic Testing Market, By Procedure:

• Preimplantation Genetic Screening
• Preimplantation Genetic Diagnosis

• Preimplantation Genetic Testing Market, By Product:

• Reagents and Consumables
• Instruments
• Software

• Preimplantation Genetic Testing Market, By Technology:

• Next Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescent In-Situ Hybridization (FISH)
• Others

• Preimplantation Genetic Testing Market, By Application:

• Chromosomal Abnormalities
• X-linked Diseases
• Embryo Testing
• Aneuploidy Screening
• HLA Typing
• Other

• Preimplantation Genetic Testing Market, By End User:

• Fertility Centers
• Hospitals
• Diagnostic Centers
• Research Centers
• Academic Labs

• Preimplantation Genetic Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE